Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,238
  • Shares Outstanding, K 69,092
  • Annual Sales, $ 70 K
  • Annual Income, $ -84,950 K
  • EBIT $ -87 M
  • EBITDA $ -84 M
  • 60-Month Beta 1.70
  • Price/Sales 1,679.47
  • Price/Cash Flow N/A
  • Price/Book 4.38

Options Overview Details

View History
  • Implied Volatility 293.90% (-83.72%)
  • Historical Volatility 41.47%
  • IV Percentile 66%
  • IV Rank 27.07%
  • IV High 908.26% on 08/07/25
  • IV Low 65.86% on 05/05/25
  • Expected Move (DTE 3) 0.3060 (18.87%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 41
  • Volume Avg (30-Day) 601
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 13,889
  • Open Int (30-Day) 21,937
  • Expected Range 1.3159 to 1.9279

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.31
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5300 +6.21%
on 03/23/26
1.9350 -16.02%
on 02/25/26
-0.2650 (-14.02%)
since 02/24/26
3-Month
1.4700 +10.54%
on 01/20/26
2.3050 -29.50%
on 12/26/25
-0.6250 (-27.78%)
since 12/24/25
52-Week
1.3000 +25.00%
on 07/15/25
2.9789 -45.45%
on 09/09/25
-0.2550 (-13.56%)
since 03/24/25

Most Recent Stories

More News
INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).

INO : 1.6000 (-0.62%)
INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , March 23, 2026 /PRNewswire/ --

INO : 1.6000 (-0.62%)
INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options

INO : 1.6000 (-0.62%)
Robbins LLP Reminds Inovio Pharmaceuticals, Inc. Stockholders of the Pending Class Action Against INO and Urges Harmed Stockholders to Seek More Information

Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October...

INO : 1.6000 (-0.62%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and certain...

INO : 1.6000 (-0.62%)
INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , March 18, 2026 /PRNewswire/ --

INO : 1.6000 (-0.62%)
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options

INO : 1.6000 (-0.62%)
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options

INO : 1.6000 (-0.62%)
INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).

INO : 1.6000 (-0.62%)
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , March 16, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

INO : 1.6000 (-0.62%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 1.7333
2nd Resistance Point 1.6767
1st Resistance Point 1.6433
Last Price 1.6000
1st Support Level 1.5533
2nd Support Level 1.4967
3rd Support Level 1.4633

See More

52-Week High 2.9789
Fibonacci 61.8% 2.3376
Fibonacci 50% 2.1395
Fibonacci 38.2% 1.9413
Last Price 1.6000
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.